CochranLab(@CochranLab) 's Twitter Profileg
CochranLab

@CochranLab

ID:2903236884

calendar_today18-11-2014 04:36:25

204 Tweets

842 Followers

868 Following

Jack Silberstein(@Jack_Silb) 's Twitter Profile Photo

I'm excited to share our work 'Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function' that's now out in PNAS! 1/3

Link to paper: pnas.org/doi/10.1073/pn…

Link to press release: news.stanford.edu/2024/03/11/pro…

account_circle
Brett Garabedian(@BrettGarabedian) 's Twitter Profile Photo

It takes two (LAG3) to tango🕺“…preventing LAG-3 homodimerization by either mutation or antibody binding…can rescue T cells from LAG-3-mediated inhibition…an opportunity to utilize LAG-3 dimer disruption in cancer .” ⁦CochranLab⁩👏 pnas.org/doi/10.1073/pn…

account_circle
Carolyn Bertozzi(@CarolynBertozzi) 's Twitter Profile Photo

Nice piece on exciting new work from CochranLab Stanford Engineering, structure of immune therapy target LAG-3 bound to agonist antibody showing importance of disrupting dimer interface, just published PNASNews

news.stanford.edu/2024/03/11/pro…

account_circle
BioTM_Buzz(@BioTM_Buzz) 's Twitter Profile Photo

The CochranLab @StanfordBioE engineered an IL-11 variant that binds with higher affinity to the IL-11 receptor, blocking IL-11-mediated cell signaling and slowing tumor growth in a mouse model of lung
bit.ly/3YQSlHs
@WileyEngineer

account_circle
ACIR(@ACIR_org) 's Twitter Profile Photo

In the physiologically relevant MMTV-PyMT GEMM model, Caitlyn Miller Idit Sagiv-Barfi Carolyn Bertozzi demonstrated that systemic delivery of a tumor integrin-targeted TLR9 agonist (PIP-CpG) led to sustained elimination [...] bit.ly/3Cu9QTC

In the physiologically relevant MMTV-PyMT GEMM model, @CaitlynBioE @BarfiIdit @CarolynBertozzi demonstrated that systemic delivery of a tumor integrin-targeted TLR9 agonist (PIP-CpG) led to sustained elimination [...] bit.ly/3Cu9QTC
account_circle
Caitlyn Miller(@CaitlynBioE) 's Twitter Profile Photo

Thrilled to announce that our new PIP-CpG paper is now live J Immunol . PIP-CpG is a tumor-targeting immunotherapy that is in preclinical development & we are hoping to advance it to the clinic in the coming years. doi.org/10.4049/jimmun… .
A 🧵👇(1/13)

Thrilled to announce that our new PIP-CpG paper is now live @J_Immunol . PIP-CpG is a tumor-targeting immunotherapy that is in preclinical development & we are hoping to advance it to the clinic in the coming years. doi.org/10.4049/jimmun… . A 🧵👇(1/13)
account_circle
Carolyn Bertozzi(@CarolynBertozzi) 's Twitter Profile Photo

Congratulations ⁦Michael Hollander⁩ and coworkers ⁦Stacy Malaker, Idalia Perez,⁩ ⁦Julia Maxson⁩ and ⁦CochranLab⁩ on this new preprint. CSF3R signaling is regulated by , mutations at glycosites can drive cancer progression. biorxiv.org/content/10.110…

account_circle
PEGS Summit(@PEGSboston) 's Twitter Profile Photo

Join Plenary Keynote Jennifer Cochran, PhD, today at 4:10pm to discuss challenges and opportunities in developing non-antibody protein therapeutics. pegsummit.com/plenary-keynote

Join #PEGS22 Plenary Keynote Jennifer Cochran, PhD, today at 4:10pm to discuss challenges and opportunities in developing non-antibody protein therapeutics. pegsummit.com/plenary-keynote
account_circle
Alina Chrzastek(@Evoletto) 's Twitter Profile Photo

TLR9 (CpG) agonist was chemically conjugated to polyspecific integrin-binding peptide (PIP) that is capable to localise various types of solid tumours as explained by Caitlyn Miller from CochranLab at Stanford University PEGS Summit

TLR9 (CpG) agonist was chemically conjugated to polyspecific integrin-binding peptide (PIP) that is capable to localise various types of solid tumours as explained by Caitlyn Miller from @CochranLab at @Stanford #PEGS22 @PEGSboston
account_circle
CochranLab(@CochranLab) 's Twitter Profile Photo

Excited to share this collaborative work published in Cell on an exquisite drug-regulated CAR platform. Led by Louai Labanieh, jointly advised Bioengineering PhD student in the lab of Crystal Mackall

account_circle
Cell Press(@CellPressNews) 's Twitter Profile Photo

Read Jennifer Cochran's recent CellChemicalBiology article: Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression CochranLab hubs.li/Q017Kf5f0

account_circle
Majzner_Lab(@Majzner_Lab) 's Twitter Profile Photo

Happy to share our lab's first manuscript. In work led by Johanna Theruvath, we tested a combo of FDA approved anti-GD2 with blockade of CD47, a macrophage checkpoint. Blocking CD47 unleashes patients' macrophages to phagocytose or 'eat' cancer cells. Combo was highly effective! 1/

account_circle
CochranLab(@CochranLab) 's Twitter Profile Photo

On July 19, learn about how next-generation engineered proteins target stromal factors can remodel an immunosuppressive tumor microenvironment at the

On July 19, learn about how next-generation engineered proteins target stromal factors can remodel an immunosuppressive tumor microenvironment at the #PEGSymposium
account_circle
CochranLab(@CochranLab) 's Twitter Profile Photo

The Cochran Lab at Stanford is seeking a Research Scientist (LSRP3) to join our stellar protein engineering team. Join us to develop the next generation of protein therapeutics! careersearch.stanford.edu/jobs/life-scie…

account_circle